Clinical trials
catalyst calendar across sponsors →Studies where VYGR is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
3 interventional
Held by 12 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, TWO SIGMA INVESTMENTS, LP, CITADEL ADVISORS LLC, RENAISSANCE TECHNOLOGIES LLC, AQR CAPITAL MANAGEMENT LLC, +7 more) · FINRA short interest 5.8 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's DiseaseNCT07764146To characterize the safety and tolerability in participants with AD by Incidence of treatment emergent adverse events, changes from baseline in vital signs, physical and neurological exams and other safety measuresNon-randomized · Open-label · Treatment | Phase 1 | Not yet recruiting | Drug: VY1706 Low dose, VY1706 Mid dose, VY1706 High Dose · Device: Anti-AAV9 Total Antibody (TAb) Assay | Alzheimer s Disease | 18 | 2029-04-28 | in 983 d | 2026-08-13 |
| VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's DiseaseNCT06874621Characterization of the safety and tolerability of VY7523 in participants with early ADRandomized · Quadruple-masked · Treatment | Phase 1/2 | Active, not recruiting | Drug: VY7523, Placebo Comparator | Alzheimer's Disease (AD) | 52 | May 2027 | ≤ 285 d | 2025-11-19 |
| Safety and Tolerability Study With VY-HTT01, in Adults With Early Manifesting Huntington's DiseaseNCT04885114Incidence and type of AEsRandomized · Open-label · Treatment | Phase 1 | Withdrawnsponsor's stated reason: We have discontinued our 1st generation HD program with the VYTAL Study \& have initiated a 2nd generation program using a novel, proprietary AAV capsid that may enable intravenous administration \& achieve widespread distribution to affected tissue. | Genetic: Intraparenchymal rAAV1 - (mi)RNA HTT | Huntington Disease | 0 | 2024-12-30 | — | 2021-08-16 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19